Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.33 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.33 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.32 |
| ▸ | BUB1 | O43683 | 1/20 | 0.32 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.31 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21042589 | 0.88 | L3MBTL1 (0.36) | L3MBTL1BCHEPOLBTNK2GPR119 | |
| SCHEMBL16606149 | 0.86 | POLB (0.37) | L3MBTL1BCHEGABRG2GABRB3GABRA5 | |
| SCHEMBL16606153 | 0.85 | CFTR (0.37) | BCHEGABRG2GABRB3GABRA5POLB | |
| SCHEMBL16606151 | 0.83 | GPR119 (0.37) | GPR119 | |
| SCHEMBL16593422 | 0.82 | CCR1 (0.36) | L3MBTL1 | |
| SCHEMBL10072162 | 0.79 | GPR119 (0.35) | L3MBTL1BCHEGABRG2GABRB3GABRA5 | |
| SCHEMBL16593587 | 0.78 | L3MBTL1 (0.43) | L3MBTL1BCHEGABRG2GABRB3GABRA5 | |
| SCHEMBL17179359 | 0.76 | L3MBTL1 (0.43) | L3MBTL1BCHEGPR119BUB1HSP90AA1 | |
| SCHEMBL14605052 | 0.75 | POLB (0.42) | L3MBTL1BCHEGABRG2GABRB3GABRA5 | |
| SCHEMBL31751884 | 0.74 | BCHE (0.35) | L3MBTL1BCHEGABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3489237-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3489237-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2020-05-13 | — | — | EP | disclosed |
| EP-3489237-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3489237-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2019-05-29 | — | — | EP | disclosed |
| EP-3052496-B1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2018-11-28 | — | — | EP | disclosed |
| US-10072005-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-09-11 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-20180208593-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-07-26 | — | — | US | disclosed |
| US-9926312-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-9926312-B2 | 4-azaindole derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-03-27 | — | — | US | disclosed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| US-20160244445-A1 | 4-Azaindole Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-08-25 | — | — | US | disclosed |
| EP-3052496-A1 | 4-AZAINDOLE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015049574-A1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015049574-A1 | 4-AZAINDOLE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-09 | — | — | WO | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
| US-20150094328-A1 | 4-Azaindole Derivatives | EISAI R&D MAN CO LTD (JP) | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10072005-B2 | 4-azaindole derivatives | CHRM1, CHRM4, CHRM2 | L3MBTL1 1762/4885BCHE 29/4885GABRG2 501/4885 |
| US-20160244445-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | L3MBTL1 1762/4885BCHE 29/4885GABRG2 501/4885 |
| US-20180208593-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | L3MBTL1 1762/4885BCHE 29/4885GABRG2 501/4885 |
| US-20150094328-A1 | 4-Azaindole Derivatives | CHRM1, CHRM4, CHRM2 | L3MBTL1 1762/4885BCHE 29/4885GABRG2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.